208 related articles for article (PubMed ID: 29210059)
1. Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
Huang L; Qin Y; Zuo Q; Bhatnagar K; Xiong J; Merlino G; Yu Y
Int J Cancer; 2018 Apr; 142(8):1652-1663. PubMed ID: 29210059
[TBL] [Abstract][Full Text] [Related]
2. FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
Cui YM; Jiao HL; Ye YP; Chen CM; Wang JX; Tang N; Li TT; Lin J; Qi L; Wu P; Wang SY; He MR; Liang L; Bian XW; Liao WT; Ding YQ
Oncogene; 2015 Aug; 34(33):4379-90. PubMed ID: 25381815
[TBL] [Abstract][Full Text] [Related]
3. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development.
Li G; Schaider H; Satyamoorthy K; Hanakawa Y; Hashimoto K; Herlyn M
Oncogene; 2001 Dec; 20(56):8125-35. PubMed ID: 11781826
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
Hwang S; Kim HE; Min M; Raghunathan R; Panova IP; Munshi R; Ryu B
J Invest Dermatol; 2015 Sep; 135(9):2283-2291. PubMed ID: 25910030
[TBL] [Abstract][Full Text] [Related]
6. Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion.
Kwak IH; Shin YH; Kim M; Cha HY; Nam HJ; Lee BS; Chaudhary SC; Pai KS; Lee JH
Exp Mol Med; 2011 Feb; 43(2):111-20. PubMed ID: 21209554
[TBL] [Abstract][Full Text] [Related]
7. Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model.
Yu Y; Merlino G
Cancer Res; 2002 May; 62(10):2951-6. PubMed ID: 12019177
[TBL] [Abstract][Full Text] [Related]
8. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
9. HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1.
Gaggioli C; Deckert M; Robert G; Abbe P; Batoz M; Ehrengruber MU; Ortonne JP; Ballotti R; Tartare-Deckert S
Oncogene; 2005 Feb; 24(8):1423-33. PubMed ID: 15608673
[TBL] [Abstract][Full Text] [Related]
10. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
11. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype.
Otsuka T; Takayama H; Sharp R; Celli G; LaRochelle WJ; Bottaro DP; Ellmore N; Vieira W; Owens JW; Anver M; Merlino G
Cancer Res; 1998 Nov; 58(22):5157-67. PubMed ID: 9823327
[TBL] [Abstract][Full Text] [Related]
12. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro.
Su W; Gutmann DH; Perry A; Abounader R; Laterra J; Sherman LS
Glia; 2004 Feb; 45(3):297-306. PubMed ID: 14730703
[TBL] [Abstract][Full Text] [Related]
13. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
14. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia.
Kentsis A; Reed C; Rice KL; Sanda T; Rodig SJ; Tholouli E; Christie A; Valk PJ; Delwel R; Ngo V; Kutok JL; Dahlberg SE; Moreau LA; Byers RJ; Christensen JG; Vande Woude G; Licht JD; Kung AL; Staudt LM; Look AT
Nat Med; 2012 Jul; 18(7):1118-22. PubMed ID: 22683780
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies using miR-32-5p to suppress clear cell renal cell carcinoma metastasis via altering the miR-32-5p/TR4/HGF/Met signaling.
Wang M; Sun Y; Xu J; Lu J; Wang K; Yang DR; Yang G; Li G; Chang C
Int J Cancer; 2018 Jul; 143(1):100-112. PubMed ID: 29396852
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma.
Bendinelli P; Maroni P; Matteucci E; Desiderio MA
Cell Death Dis; 2017 Feb; 8(2):e2578. PubMed ID: 28151481
[TBL] [Abstract][Full Text] [Related]
17. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.
Demkova L; Kucerova L
Mol Cancer; 2018 Feb; 17(1):26. PubMed ID: 29455657
[TBL] [Abstract][Full Text] [Related]
18. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells.
Jeffers M; Rong S; Anver M; Vande Woude GF
Oncogene; 1996 Aug; 13(4):853-6. PubMed ID: 8761307
[TBL] [Abstract][Full Text] [Related]
19. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
20. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
Kou J; Musich PR; Staal B; Kang L; Qin Y; Yao ZQ; Zhang B; Wu W; Tam A; Huang A; Hao HX; Vande Woude GF; Xie Q
J Transl Med; 2018 Sep; 16(1):253. PubMed ID: 30208970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
